Arcus Biosciences, Inc. (RCUS) revenue and earnings history
Arcus Biosciences, Inc. reported revenue of $247M for fiscal 2025 (year ended Dec 31, 2025), −4.3% on the year before, and net income of −$353M.
Over 8 years, from fiscal 2017 to fiscal 2025, revenue grew at a compound rate of +90.7% a year.
Revenue and net income, 10 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $247M−4.3% | −$386M | −$353M | −$482M | $2M | −$484M | $60M | — | — | $222M | $99M | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Arcus Biosciences, Inc. (RCUS) on OQRO.
Common questions
What was Arcus Biosciences, Inc.'s revenue in fiscal 2025?
$247M for the year ended Dec 31, 2025, as reported in its 10-K filed Feb 25, 2026. That is −4.3% on fiscal 2024 ($258M).
How fast has Arcus Biosciences, Inc.'s revenue grown?
From $1.41M in fiscal 2017 to $247M in fiscal 2025: a compound annual growth rate of +90.7% over 8 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Arcus Biosciences, Inc. tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.